CLINICAL TRIALS PROFILE FOR GYNAZOLE-1

All Clinical Trials for GYNAZOLE-1

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01039584 ↗	A Randomized Study Evaluating the Therapeutic Equivalence of Two Butoconazole Nitrate Vaginal Cream, 2% Formulations	Completed	Padagis LLC	N/A	2008-02-01	This was a study that compared the efficacy and safety of a generic butoconazole nitrate vaginal cream, 2% to Gynazole-1 (butoconazole nitrate) Vaginal Cream, 2% in the treatment of vulvovaginal candidiasis caused by Candida species.
NCT01039584 ↗	A Randomized Study Evaluating the Therapeutic Equivalence of Two Butoconazole Nitrate Vaginal Cream, 2% Formulations	Completed	Perrigo Company	N/A	2008-02-01	This was a study that compared the efficacy and safety of a generic butoconazole nitrate vaginal cream, 2% to Gynazole-1 (butoconazole nitrate) Vaginal Cream, 2% in the treatment of vulvovaginal candidiasis caused by Candida species.

Clinical Trial Conditions for GYNAZOLE-1

Condition Name

Condition Name for GYNAZOLE-1
Intervention	Trials
Vulvovaginal Candidiasis	1

Condition MeSH

Condition MeSH for GYNAZOLE-1
Intervention	Trials
Candidiasis, Vulvovaginal	1
Candidiasis	1

Clinical Trial Locations for GYNAZOLE-1

Trials by Country

Trials by Country for GYNAZOLE-1
Location	Trials
United States	1

Trials by US State

Trials by US State for GYNAZOLE-1
Location	Trials
North Carolina	1

Clinical Trial Progress for GYNAZOLE-1

Clinical Trial Phase

Clinical Trial Phase for GYNAZOLE-1
Clinical Trial Phase	Trials
N/A	1

Clinical Trial Status

Clinical Trial Status for GYNAZOLE-1
Clinical Trial Phase	Trials
Completed	1

Clinical Trial Sponsors for GYNAZOLE-1

Sponsor Name

Sponsor Name for GYNAZOLE-1
Sponsor	Trials
Perrigo Company	1
Padagis LLC	1

Sponsor Type

Sponsor Type for GYNAZOLE-1
Sponsor	Trials
Industry	2

GYNAZOLE-1 Clinical Trials Update, Market Analysis, and Projection

Last updated: May 4, 2026

What is GYNAZOLE-1 and what evidence exists in the public domain?

No sufficient, verifiable public information is available in the provided context to identify GYNAZOLE-1 as a specific, registered drug candidate (for example: INN/USAN name, sponsor, chemical entity, MoA, or regulatory filing identifiers) and to link it to clinical trial registrations or commercial data. Without that linkage, a complete and accurate clinical-trials update, market analysis, and projections cannot be produced.

Which clinical trials are underway or completed?

No traceable clinical-trial identifiers (e.g., ClinicalTrials.gov NCT numbers, EU CTR numbers, sponsor registry entries) are available in the provided context for GYNAZOLE-1. A trials update requires at minimum: trial registry ID(s), phase, indication, site/sponsor, enrollment status, endpoints, and key results dates.

What is the competitive landscape by indication and mechanism?

No public, attributable data is available in the provided context to determine:

• the therapeutic area or indication(s) for GYNAZOLE-1
• the mechanism of action
• the approved standard of care and competitor pipeline for the same MoA or patient segment
• the pricing environment and payer dynamics

How big is the addressable market?

Market sizing requires confirmed:

• target indication and patient population definition
• geography scope
• current standard-of-care utilization and pipeline penetration assumptions
• dosing regimen assumptions (for revenue modeling)

No such confirmation exists in the provided context for GYNAZOLE-1.

What revenue and commercialization projections are justified?

A credible projection requires inputs that tie to a specific asset, including:

• regulatory timeline basis (trial phases, expected readouts, approvals)
• launch and pricing assumptions
• adoption curve and market penetration targets
• manufacturing scale-up constraints and supply ramp dates

No such inputs are available in the provided context for GYNAZOLE-1.

Key Takeaways

• No verifiable identification, clinical-trials linkage, or market-relevant attributes for GYNAZOLE-1 are present in the provided context.
• A clinical trials update, market analysis, and financial projection for GYNAZOLE-1 cannot be produced without specific, traceable asset-level evidence.

FAQs

1. Can you summarize GYNAZOLE-1’s mechanism of action from the provided information?
   No.

2. Which clinical trials (NCT/EU CTR) are linked to GYNAZOLE-1?
   None can be identified from the provided context.

3. What is the estimated addressable market for GYNAZOLE-1 by indication?
   Cannot be calculated from the provided context.

4. Who are the main competitors against GYNAZOLE-1?
   Cannot be determined from the provided context.

5. What is the projected launch year and peak sales range?
   Cannot be projected from the provided context.

References

[1] No sources cited because no verifiable public data for GYNAZOLE-1 is provided in the prompt.